Fig. 2: Subgroup analyses on progression-free survival (PFS) according to baseline factors. | Blood Cancer Journal

Fig. 2: Subgroup analyses on progression-free survival (PFS) according to baseline factors.

From: Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Fig. 2

Multivariate subgroup analyses adjusted for response (CR/nCR vs.<nCR) were calculated for PFS in the overall cohort. ISS international staging system, rISS revised ISS, cytogenetic risk: high vs. standard [=low] risk, Elevated LDH (elevated [yes] vs. normal [no]), RI renal impairment, defined as serum creatinine (>2 mg/dl [yes] vs. <2 mg/dl [no]); Hyperdiploidy cytogenetic hyperdiploidy [HD].

Back to article page